Gass J D
Arch Ophthalmol. 1985 Jul;103(7):916-23.
Between December 1962 and May 1979, growth of choroidal and ciliary body melanomas was documented in 34 patients prior to enucleation. Twenty-seven of the 34 patients underwent enucleation during the same time period (1967 through 1976), when primary treatment with a cobalt 60 episcleral plaque was employed in a nonrandomized fashion in 21 patients with similar-sized melanomas. Comparison of these two groups of patients, none of whom was unavailable for follow-up and all of whom were followed up for a minimum of 66 months, showed that the probability of dying of metastatic melanoma within five years after cobalt 60 therapy was 50% compared with 16% after enucleation. Factors of potential importance in explaining this difference included nonrandomization, small number of patients in both groups, and greater frequency of anterior location of tumors in the cobalt 60 group (76% vs 22%). A randomized, controlled clinical trial is required to determine the relative safety of treatment for uveal melanomas.
1962年12月至1979年5月期间，34例患者在眼球摘除术前记录了脉络膜和睫状体黑色素瘤的生长情况。34例患者中有27例在同一时期（1967年至1976年）接受了眼球摘除术，当时对21例黑色素瘤大小相似的患者以非随机方式采用钴60巩膜外斑块进行了初步治疗。对这两组患者进行比较，两组患者均可进行随访，且均至少随访了66个月，结果显示，钴60治疗后五年内死于转移性黑色素瘤的概率为50%，而眼球摘除术后为16%。在解释这种差异方面可能具有重要意义的因素包括非随机化、两组患者数量少以及钴60组肿瘤位于前部的频率更高（76%对22%）。需要进行一项随机对照临床试验来确定葡萄膜黑色素瘤治疗的相对安全性。
